Study linking outcome in acute coronary syndromes to anti-PC published in International Journal of Cardiology
(Thomson Reuters ONE) -
Solna, Sweden, February 7th, 2012 - Scientists conclude that measuring
antibodies to phosporylcholine (anti-PC), using a simple blood-test, may provide
important and independent information on the prognosis of heart attack patients,
in a study just published on-line in International Journal of Cardiology. The
testing was performed using Athera Biotechnologies CVDefine® kit.
Already published studies have reported that low levels of anti-PC in healthy
individuals are linked to development of atherosclerosis and serious
cardiovascular consequences like heart attack and stroke. This study measured
anti-PC levels in samples from 1185 acute coronary syndrome (ACS) patients and
shows for the first time that low anti-PC levels indicate poor prognosis in
these patients, with a high risk for new cardiovascular events and even death.
The scientists suggest that low levels of anti-PC might give an insufficient
protection to counteract vascular inflammation and the risk of plaque rupture.
Low anti-PC levels may therefore represent a new paradigm for reporting reduced
atheroprotection in heart disease and identify patients in need of more intense
treatment to prevent secondary events.
"We are in active development of an anti-inflammatory antibody therapy for
prevention of secondary cardiovascular events in myocardial infarction patients
with low levels of anti-PC. These new findings strengthens the therapeutic
approach with a companion diagnostics potential and suggests that increasing
anti-PC levels in these patients could have a beneficial effect on outcomes",
says Carina Schmidt, CEO of Athera
About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components
in atherosclerosis, the inflammatory process leading to cardiovascular disease
(CVD). The company currently has two biopharmaceutical product candidates aimed
at treating patients with cardiovascular conditions and a biomarker linked to
the therapeutic approach.
PC-mAb from Athera is in late pre-clinical development, using a unique fully
human monoclonal antibody. PC-mAb is being developed to restore cardio-
protective levels of anti-PC and prevent secondary CVD events after acute
coronary syndrome.
In addition, Athera has developed a biomarker and companion diagnostic CVDefine®
kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular
disease and could in the future be used for identification of patients that
benefit from Athera's novel therapeutics.
Athera, a Swedish company, is part of the Karolinska Development AB (publ)
portfolio. www.athera.se
For further Information:
Athera Biotechnologies AB (publ)
Chief Executive Officer
Carina Schmidt
Tel +46 761938190
c.schmidt(at)athera.se
News Release as PDF:
http://hugin.info/143298/R/1583251/494918.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Athera Biotechnologies AB via Thomson Reuters ONE
[HUG#1583251]
Unternehmensinformation / Kurzprofil:
Datum: 07.02.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 111916
Anzahl Zeichen: 3864
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Study linking outcome in acute coronary syndromes to anti-PC published in International Journal of Cardiology"
steht unter der journalistisch-redaktionellen Verantwortung von
Athera Biotechnologies AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
